– EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic –
SOUTH SAN FRANCISCO, CA, USA I May 26, 2022 I CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 (NCT05387265). CX-904 is a conditionally activated T-cell-engaging bispecific (TCB) designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells within the tumor microenvironment.
“The successful initiation of this first-in-human study represents another major milestone for CytomX, as it marks the third therapeutic modality to enter the clinic from our versatile Probody platform,” said Amy C. Peterson, M.D., president and chief operating officer at CytomX Therapeutics. “Our conditionally activated TCB platform is designed to localize both target binding and T-cell activation selectively to the tumor microenvironment, minimizing extra-tumoral activation of T cells and potentially widening the therapeutic window for solid tumor-directed TCBs. This study underscores our commitment to destroying cancer differently and bolsters our leadership in the field of conditional activation in oncology.”
Utilizing CytomX’s proprietary masking technology to reduce systemic target engagement, conditionally activated TCBs are constructed to direct the activity of CD3-positive, cytotoxic T cells to cancer cells expressing the target of interest, with the goal of improving the therapeutic window of these highly potent agents for the treatment of solid tumors. CytomX has shown in preclinical models that dual-masked, conditionally activated TCBs targeting EGFR and CD3 have the potential for an improved therapeutic window compared to conventional, unmasked TCBs.
“We look forward to exploring CX-904 in solid tumors,” said Meredith Pelster, M.D., MSCI, a study investigator at Sarah Cannon Research Institute at Tennessee Oncology. “Given that EGFR is widely expressed in a number of solid tumors, the opportunity for this therapeutic candidate to address an unmet need in multiple tumor types is noteworthy.”
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments by successfully leveraging therapeutic targets that were once thought to be inaccessible. CytomX’s robust and differentiated pipeline includes the wholly-owned praluzatamab ravtansine, an investigational conditionally activated antibody-drug conjugate (ADC) directed toward CD166, and CX-2029, an investigational conditionally activated ADC directed toward CD71 being developed in collaboration with AbbVie. These two programs are currently being evaluated in Phase 2 studies, targeting a variety of late-stage, difficult-to-treat cancer types, including breast cancer for praluzatamab ravtansine, and squamous non-small cell lung cancer, and head and neck squamous cell carcinoma for CX-2029. CytomX’s clinical pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and our wholly-owned conditionally activated anti-PD-L1 antibody, pacmilimab, as well as CX-904, a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells, which is partnered with Amgen. In addition, CytomX has a diverse preclinical portfolio and strategic collaborations with multiple leaders in oncology, including AbbVie, Amgen, Astellas, and Bristol Myers Squibb. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and Twitter.
SOURCE: CytomX Therapeutics
Post Views: 338
– EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic –
SOUTH SAN FRANCISCO, CA, USA I May 26, 2022 I CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that the first patient has been dosed in a Phase 1 dose-escalation study of CX-904 (NCT05387265). CX-904 is a conditionally activated T-cell-engaging bispecific (TCB) designed to target the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells within the tumor microenvironment.
“The successful initiation of this first-in-human study represents another major milestone for CytomX, as it marks the third therapeutic modality to enter the clinic from our versatile Probody platform,” said Amy C. Peterson, M.D., president and chief operating officer at CytomX Therapeutics. “Our conditionally activated TCB platform is designed to localize both target binding and T-cell activation selectively to the tumor microenvironment, minimizing extra-tumoral activation of T cells and potentially widening the therapeutic window for solid tumor-directed TCBs. This study underscores our commitment to destroying cancer differently and bolsters our leadership in the field of conditional activation in oncology.”
Utilizing CytomX’s proprietary masking technology to reduce systemic target engagement, conditionally activated TCBs are constructed to direct the activity of CD3-positive, cytotoxic T cells to cancer cells expressing the target of interest, with the goal of improving the therapeutic window of these highly potent agents for the treatment of solid tumors. CytomX has shown in preclinical models that dual-masked, conditionally activated TCBs targeting EGFR and CD3 have the potential for an improved therapeutic window compared to conventional, unmasked TCBs.
“We look forward to exploring CX-904 in solid tumors,” said Meredith Pelster, M.D., MSCI, a study investigator at Sarah Cannon Research Institute at Tennessee Oncology. “Given that EGFR is widely expressed in a number of solid tumors, the opportunity for this therapeutic candidate to address an unmet need in multiple tumor types is noteworthy.”
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company dedicated to destroying cancer differently. By pioneering a novel class of conditionally activated biologics, powered by its Probody® technology platform, CytomX’s goal is to transcend the limits of current cancer treatments by successfully leveraging therapeutic targets that were once thought to be inaccessible. CytomX’s robust and differentiated pipeline includes the wholly-owned praluzatamab ravtansine, an investigational conditionally activated antibody-drug conjugate (ADC) directed toward CD166, and CX-2029, an investigational conditionally activated ADC directed toward CD71 being developed in collaboration with AbbVie. These two programs are currently being evaluated in Phase 2 studies, targeting a variety of late-stage, difficult-to-treat cancer types, including breast cancer for praluzatamab ravtansine, and squamous non-small cell lung cancer, and head and neck squamous cell carcinoma for CX-2029. CytomX’s clinical pipeline also includes cancer immunotherapeutic candidates against validated targets such as the CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288, partnered with Bristol Myers Squibb, and our wholly-owned conditionally activated anti-PD-L1 antibody, pacmilimab, as well as CX-904, a conditionally activated T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells, which is partnered with Amgen. In addition, CytomX has a diverse preclinical portfolio and strategic collaborations with multiple leaders in oncology, including AbbVie, Amgen, Astellas, and Bristol Myers Squibb. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and Twitter.
SOURCE: CytomX Therapeutics
Post Views: 338
